T-DM1 + Pembrolizumab: safety and tolerability assessment: In 2017, a phase 1b study (NCT03032107) was conducted to assess the safety and determine the appropriate dose for the combination of T-DM1 and pembrolizumab in metastatic HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.